The Prevention of Delirium and Complications Associated With Surgical Treatments Multi Center Clinical Trial (PODCAST)
Primary Purpose
Delirium
Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Ketamine (0.5 mg/kg)
Normal Saline (placebo)
Ketamine (1 mg/kg)
Sponsored by
About this trial
This is an interventional prevention trial for Delirium focused on measuring Delirium, ketamine, surgery, neurological complications
Eligibility Criteria
Inclusion Criteria:
- Patients 60 and older
- Competent to provide informed consent
- Undergoing major surgery (e.g., open cardiac surgery, open or thoracoscopic thoracic surgery, abdominal surgery, open urological surgery, open gynecological surgery, major orthopedic surgery, major vascular surgery including endovascular procedures, major ear, nose and throat surgery).
Exclusion Criteria:
- Patients with an allergy to ketamine
- Those in whom a significant elevation of blood pressure would constitute a serious hazard (e.g., pheochromocytoma, aortic dissection)
- Unable to provide informed consent
- Patients with drug misuse history (e.g., ketamine, cocaine, heroin, amphetamine, methamphetamine, MDMA, phencyclidine, lysergic acid, mescaline, psilocybin)
- Patients taking anti-psychotic medications (e.g., chlorpromazine, clozapine, olanzapine, risperidone, haloperidol, quetiapine, risperidone, paliperidone, amisulpride, sertindole)
- Patients with a weight outside the range 50 kg - 200 kg (110 lbs - 440 lbs)
Sites / Locations
- Washington University School of Medicine
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Placebo Comparator
Experimental
Arm Label
Ketamine (0.5 mg/kg)
Normal saline (placebo)
Ketamine (1 mg/kg)
Arm Description
Low dose (sub-anesthetic) 0.5 mg/kg ketamine following induction of anesthesia or administration of sedative medications.
Intravenous normal saline
Low dose (sub-anesthetic) 1 mg/kg ketamine following induction of anesthesia or administration of sedative medications.
Outcomes
Primary Outcome Measures
Number of Patients With Incidence of Delirium Across All Patients at Baseline and Over Post-operative Days 1-3
According to Confusion Assessment Method or Confusion Assessment Method for Intensive Care Unit criteria the number of patients that had any positive CAM on any day for all patients. The main effect evaluated will be to determine whether ketamine decreases delirium, table 3 of the protocol provides a useful guide for the potential findings of the current study with their implications.
To further clarify, delirium will be assessed on the day of surgery, when possible and on the subsequent three days POD 1-3, as long as as patients remain in the hospital and are assessable (i.e., not sedated to a RASS <-3). The assessments on POD 1-3 will be done twice daily, once in the morning and once in the afternoon. The primary outcome of the study includes only the delirium incidence on POD 1-3.
The primary comparison will be between the combined ketamine groups and the placebo group.
Secondary Outcome Measures
Daily Maximum Pain Recorded
Assessed by observer-based Behavioral Pain Scale or Behavioral Pain Scale (Non-Intubated) with subsequent administration of patient-reported Visual Analog Scale The behavioral pain scale has three domains and ranges from 3 to 15. The visual analog scale is a continuous scale from 0 to 100 mm. Daily Maximum Pain accounted for pain level in the AM or PM for both the VAS and the BPS/BPS-NI a higher value means a worse outcome.
Median Opioid Consumption
Assessed from patients' medical charts. All morphine equivalent drugs consumed by patients perioperatively
Opioid Drugs included:
* Postoperatively while still in hospital, the list of pain medication used included Morphine, Hydromorphone, Meperidine, Nalbuphine, Oxycodone,Oxymorphone, Tramadol, bupivacaine, (Codeine, Fentanyl, Naloxone) Total Opiates (Morphine Equivalent) in milligrams The median(IQR) opioid consumption was compared across the three study groups Placebo vs. Lo-K (0.5 mg/kg) vs. Hi-K (1 mg/kg)
Number of Patients With Postoperative Nausea and Vomiting
Assessed from patient-reported postoperative nausea and vomiting section of Behavioral Pain Scale or Behavioral Pain Scale (Non-Intubated) Patients where asked whether they "currently have nausea/vomiting" AM & PM the response choices: None, Mild, Moderate, Severe Incidence of nausea\vomiting accounted for any positive reporting(Mild, moderate, or sever) Daily incidence accounted for any positive incidence AM/PM in each POD Any POD nausea/vomiting reports the incidence across day 1-3
The incidence of nausea and or vomiting was compared across the three study groups Placebo vs. Lo-K (0.5 mg/kg) vs. Hi-K (1 mg/kg) for POD 1-3 and overall.
ICU and/or Hospital Length of Stay
Assessed from patients' medical charts
Adverse Outcomes (Number of Patients With Hallucinations)
Assessed via Confusion Assessment Method or Confusion Assessment Method for Intensive Care Unit
Adverse Outcomes (Number of Patients With Nightmares)
Assessed via Confusion Assessment Method or Confusion Assessment Method for Intensive care Unit
Full Information
NCT ID
NCT01690988
First Posted
August 7, 2012
Last Updated
May 2, 2018
Sponsor
Washington University School of Medicine
Collaborators
Asan Medical Center, Weill Medical College of Cornell University, Harvard Medical School (HMS and HSDM), Medical College of Wisconsin, Memorial Sloan Kettering Cancer Center, Postgraduate Institute of Medical Education and Research, University of Bern, University of Michigan, University of Manitoba, University Health Network, Toronto, Virginia Mason Hospital/Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT01690988
Brief Title
The Prevention of Delirium and Complications Associated With Surgical Treatments Multi Center Clinical Trial
Acronym
PODCAST
Official Title
The Prevention of Delirium and Complications Associated With Surgical Treatments Multi Center Clinical Trial
Study Type
Interventional
2. Study Status
Record Verification Date
November 2017
Overall Recruitment Status
Completed
Study Start Date
February 1, 2014 (Actual)
Primary Completion Date
June 26, 2016 (Actual)
Study Completion Date
July 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Washington University School of Medicine
Collaborators
Asan Medical Center, Weill Medical College of Cornell University, Harvard Medical School (HMS and HSDM), Medical College of Wisconsin, Memorial Sloan Kettering Cancer Center, Postgraduate Institute of Medical Education and Research, University of Bern, University of Michigan, University of Manitoba, University Health Network, Toronto, Virginia Mason Hospital/Medical Center
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Delirium is a medical term or condition that includes a temporary inability to focus attention and to think clearly. Delirium occurs commonly (10% to 70%) in patients older than 60 undergoing large surgeries. The purpose of this study is to test rigorously whether a drug called ketamine can decrease the chance that patients will experience delirium after their surgery. The investigators are also testing whether ketamine decreases postoperative pain, postoperative opioid consumption, postoperative nausea and vomiting, ICU and hospital length of stay, and adverse outcomes (e.g. hallucinations and nightmares).
Detailed Description
Postoperative delirium is one of the most common complications of major surgery, affecting between 10% and 70% of all elderly surgical patients. Delirium manifests as poor attention and inability to think logically, and is associated with longer intensive care unit and hospital stay, long lasting cognitive deterioration, and increased mortality rate. Studies have shown that a low sub-anesthetic dose of ketamine, an anesthetic drug, has the potential to decrease several postoperative complications, including delirium, pain, opioid consumption, and nausea and vomiting. Low dose ketamine would be particularly appealing as a drug to prevent delirium and other postoperative complications, as it is inexpensive and extremely safe. However, these proposed benefits of ketamine in the perioperative setting have not yet been tested in a large clinical trial. The investigators are therefore proposing a pragmatic, exploratory clinical trial to support or refute the contention that low dose ketamine decreases the incidence of postoperative delirium, with the possibility of conducting a larger randomized clinical trial pending the results of this study. At the time of enrollment, patients will undergo the same delirium and pain evaluation that will be used postoperatively. Additionally patients will be screened for functional dependence using the Barthel Index of Activities of Daily Living, for depression using the Geriatric Depression Scale - Short Form, and for obstructive sleep apnea using the STOP-Bang criteria. They will also be asked about any falls they have experienced in the six months prior to surgery. Comorbid conditions, including the components of the Charlson Comorbidity Index, will be obtained by reviewing the patients' medical records. Any available preoperative lab results, including electrolytes and blood counts, will also be recorded.
Patients will be randomized to receive low dose ketamine or placebo following induction of anesthesia and prior to surgical incision. Blinded observers will assess delirium on the afternoon/evening of postoperative day 0 (if feasible) and twice daily (morning and afternoon/evening with at least six hours between assessments) on postoperative days 1-3 using the Confusion Assessment Method or the Confusion Assessment Method for Intensive Care Unit. Acute pain will be assessed via the observer-based Behavioral Pain Scale or Behavioral Pain Scale (Non-Intubated) with subsequent administration of the patient-reported Visual Analog Scale from postoperative days 0-3. Postoperative opioid consumption will be assessed from the patients' medical charts for postoperative days 0-3. Postoperative nausea and vomiting will be assessed via a patient-reported section of the Behavioral Pain Scale or Behavioral Pain Scale (Non-Intubated) for postoperative days 0-3. ICU and/or hospital length of stay will be assessed from the patients' medical charts. Adverse outcomes (e.g. hallucinations and nightmares) will be assessed via the Confusion Assessment Method or the Confusion Assessment Method for Intensive Care Unit for postoperative days 0-3.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Delirium
Keywords
Delirium, ketamine, surgery, neurological complications
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
746 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Ketamine (0.5 mg/kg)
Arm Type
Experimental
Arm Description
Low dose (sub-anesthetic) 0.5 mg/kg ketamine following induction of anesthesia or administration of sedative medications.
Arm Title
Normal saline (placebo)
Arm Type
Placebo Comparator
Arm Description
Intravenous normal saline
Arm Title
Ketamine (1 mg/kg)
Arm Type
Experimental
Arm Description
Low dose (sub-anesthetic) 1 mg/kg ketamine following induction of anesthesia or administration of sedative medications.
Intervention Type
Drug
Intervention Name(s)
Ketamine (0.5 mg/kg)
Other Intervention Name(s)
Ketalar
Intervention Description
Low dose (sub-anesthetic) 0.5 mg/kg ketamine following induction of anesthesia or administration of sedative medications.
Intervention Type
Drug
Intervention Name(s)
Normal Saline (placebo)
Other Intervention Name(s)
Normal saline
Intervention Description
Normal saline IV following induction of anesthesia or administration of sedative medications
Intervention Type
Drug
Intervention Name(s)
Ketamine (1 mg/kg)
Other Intervention Name(s)
Ketalar
Intervention Description
Low dose (sub-anesthetic) 1 mg/kg ketamine following induction of anesthesia or administration of sedative medications.
Primary Outcome Measure Information:
Title
Number of Patients With Incidence of Delirium Across All Patients at Baseline and Over Post-operative Days 1-3
Description
According to Confusion Assessment Method or Confusion Assessment Method for Intensive Care Unit criteria the number of patients that had any positive CAM on any day for all patients. The main effect evaluated will be to determine whether ketamine decreases delirium, table 3 of the protocol provides a useful guide for the potential findings of the current study with their implications.
To further clarify, delirium will be assessed on the day of surgery, when possible and on the subsequent three days POD 1-3, as long as as patients remain in the hospital and are assessable (i.e., not sedated to a RASS <-3). The assessments on POD 1-3 will be done twice daily, once in the morning and once in the afternoon. The primary outcome of the study includes only the delirium incidence on POD 1-3.
The primary comparison will be between the combined ketamine groups and the placebo group.
Time Frame
Delirium incidence on postoperative days 1-3, calculated by any positive CAM on any day for all patients
Secondary Outcome Measure Information:
Title
Daily Maximum Pain Recorded
Description
Assessed by observer-based Behavioral Pain Scale or Behavioral Pain Scale (Non-Intubated) with subsequent administration of patient-reported Visual Analog Scale The behavioral pain scale has three domains and ranges from 3 to 15. The visual analog scale is a continuous scale from 0 to 100 mm. Daily Maximum Pain accounted for pain level in the AM or PM for both the VAS and the BPS/BPS-NI a higher value means a worse outcome.
Time Frame
Postoperative days 1-3, two assessment daily (morning and afternoon), with at least six hours between assessments
Title
Median Opioid Consumption
Description
Assessed from patients' medical charts. All morphine equivalent drugs consumed by patients perioperatively
Opioid Drugs included:
* Postoperatively while still in hospital, the list of pain medication used included Morphine, Hydromorphone, Meperidine, Nalbuphine, Oxycodone,Oxymorphone, Tramadol, bupivacaine, (Codeine, Fentanyl, Naloxone) Total Opiates (Morphine Equivalent) in milligrams The median(IQR) opioid consumption was compared across the three study groups Placebo vs. Lo-K (0.5 mg/kg) vs. Hi-K (1 mg/kg)
Time Frame
Postoperative days 0-3
Title
Number of Patients With Postoperative Nausea and Vomiting
Description
Assessed from patient-reported postoperative nausea and vomiting section of Behavioral Pain Scale or Behavioral Pain Scale (Non-Intubated) Patients where asked whether they "currently have nausea/vomiting" AM & PM the response choices: None, Mild, Moderate, Severe Incidence of nausea\vomiting accounted for any positive reporting(Mild, moderate, or sever) Daily incidence accounted for any positive incidence AM/PM in each POD Any POD nausea/vomiting reports the incidence across day 1-3
The incidence of nausea and or vomiting was compared across the three study groups Placebo vs. Lo-K (0.5 mg/kg) vs. Hi-K (1 mg/kg) for POD 1-3 and overall.
Time Frame
Postoperative days 1-3
Title
ICU and/or Hospital Length of Stay
Description
Assessed from patients' medical charts
Time Frame
Postoperative period
Title
Adverse Outcomes (Number of Patients With Hallucinations)
Description
Assessed via Confusion Assessment Method or Confusion Assessment Method for Intensive Care Unit
Time Frame
Postoperative days 1-3
Title
Adverse Outcomes (Number of Patients With Nightmares)
Description
Assessed via Confusion Assessment Method or Confusion Assessment Method for Intensive care Unit
Time Frame
Postoperative days 1-3
10. Eligibility
Sex
All
Minimum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients 60 and older
Competent to provide informed consent
Undergoing major surgery (e.g., open cardiac surgery, open or thoracoscopic thoracic surgery, abdominal surgery, open urological surgery, open gynecological surgery, major orthopedic surgery, major vascular surgery including endovascular procedures, major ear, nose and throat surgery).
Exclusion Criteria:
Patients with an allergy to ketamine
Those in whom a significant elevation of blood pressure would constitute a serious hazard (e.g., pheochromocytoma, aortic dissection)
Unable to provide informed consent
Patients with drug misuse history (e.g., ketamine, cocaine, heroin, amphetamine, methamphetamine, MDMA, phencyclidine, lysergic acid, mescaline, psilocybin)
Patients taking anti-psychotic medications (e.g., chlorpromazine, clozapine, olanzapine, risperidone, haloperidol, quetiapine, risperidone, paliperidone, amisulpride, sertindole)
Patients with a weight outside the range 50 kg - 200 kg (110 lbs - 440 lbs)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
George A Mashour, MD PhD
Organizational Affiliation
University of Michigan
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Daniel A Emmert, MD PhD
Organizational Affiliation
Washington University School of Medicine
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Kane Pryor, MBBS
Organizational Affiliation
Cornell
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Eric Jacobsohn, MB ChB
Organizational Affiliation
University of Manitoba
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Judith Hudetz, PhD
Organizational Affiliation
Medical College of Wisconsin
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Hilary P Grocott, MD
Organizational Affiliation
University of Manitoba
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Michael S Avidan, MBBCh
Organizational Affiliation
Washington University School of Medicine
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Sharon Inouye
Organizational Affiliation
Harvard Medical School (HMS and HSDM)
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Robert Veselis
Organizational Affiliation
Memorial Sloan Kettering Medical Center
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Jayant Aveek
Organizational Affiliation
Postgraduate Institute of Medical Education and Research
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Heiko Kaiser
Organizational Affiliation
University of Bern
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Stephen Choi
Organizational Affiliation
University of Toronto
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Ryan Pong
Organizational Affiliation
Virginia Mason Medical Center
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Gyujeong Noh
Organizational Affiliation
Asan Medical Center
Official's Role
Study Director
Facility Information:
Facility Name
Washington University School of Medicine
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
25231491
Citation
Avidan MS, Fritz BA, Maybrier HR, Muench MR, Escallier KE, Chen Y, Ben Abdallah A, Veselis RA, Hudetz JA, Pagel PS, Noh G, Pryor K, Kaiser H, Arya VK, Pong R, Jacobsohn E, Grocott HP, Choi S, Downey RJ, Inouye SK, Mashour GA. The Prevention of Delirium and Complications Associated with Surgical Treatments (PODCAST) study: protocol for an international multicentre randomised controlled trial. BMJ Open. 2014 Sep 17;4(9):e005651. doi: 10.1136/bmjopen-2014-005651.
Results Reference
background
PubMed Identifier
28576285
Citation
Avidan MS, Maybrier HR, Abdallah AB, Jacobsohn E, Vlisides PE, Pryor KO, Veselis RA, Grocott HP, Emmert DA, Rogers EM, Downey RJ, Yulico H, Noh GJ, Lee YH, Waszynski CM, Arya VK, Pagel PS, Hudetz JA, Muench MR, Fritz BA, Waberski W, Inouye SK, Mashour GA; PODCAST Research Group. Intraoperative ketamine for prevention of postoperative delirium or pain after major surgery in older adults: an international, multicentre, double-blind, randomised clinical trial. Lancet. 2017 Jul 15;390(10091):267-275. doi: 10.1016/S0140-6736(17)31467-8. Epub 2017 May 30. Erratum In: Lancet. 2017 Jul 15;390(10091):230.
Results Reference
result
PubMed Identifier
30768457
Citation
Vlisides PE, Thompson A, Kunkler BS, Maybrier HR, Avidan MS, Mashour GA; PODCAST Research Group. Perioperative Epidural Use and Risk of Delirium in Surgical Patients: A Secondary Analysis of the PODCAST Trial. Anesth Analg. 2019 May;128(5):944-952. doi: 10.1213/ANE.0000000000004038.
Results Reference
derived
PubMed Identifier
30336852
Citation
Mashour GA, Ben Abdallah A, Pryor KO, El-Gabalawy R, Vlisides PE, Jacobsohn E, Lenze E, Maybrier HR, Veselis RA, Avidan MS; PODCAST Research Group. Intraoperative ketamine for prevention of depressive symptoms after major surgery in older adults: an international, multicentre, double-blind, randomised clinical trial. Br J Anaesth. 2018 Nov;121(5):1075-1083. doi: 10.1016/j.bja.2018.03.030. Epub 2018 Sep 19.
Results Reference
derived
Learn more about this trial
The Prevention of Delirium and Complications Associated With Surgical Treatments Multi Center Clinical Trial
We'll reach out to this number within 24 hrs